Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/15/2012WO2012154807A1 Use of jasmonates for modulating melatonin production and calcification of the pineal gland
11/15/2012WO2012154779A1 Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154778A1 Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154777A1 Hepatitis c virus inhibitors
11/15/2012WO2012154776A1 Combinations of trospium and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154775A1 Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154774A1 Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154771A1 Combinations of fesoterodine and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154770A1 Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
11/15/2012WO2012154759A2 Genetically engineered growth factor variants
11/15/2012WO2012154756A2 Delaying the progression of diabetes
11/15/2012WO2012154731A1 Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
11/15/2012WO2012154728A1 Deuterated n-butyl bumetanide
11/15/2012WO2012154725A2 Steroid-sparing effects of beta-adrenergic inverse agonists and use thereof
11/15/2012WO2012154710A1 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with nicotine
11/15/2012WO2012154698A2 Method to improve antiviral activity of nucleotide analogue drugs
11/15/2012WO2012154695A2 Treatment of polycystic disease
11/15/2012WO2012154685A1 Canfosfamide monotherapy for treating multiple myeloma
11/15/2012WO2012154681A1 Quantitation of gl3 in urine
11/15/2012WO2012154680A2 MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS
11/15/2012WO2012154679A1 Tricyclic pyrazole sulfonamide compounds and methods of making and using same
11/15/2012WO2012154678A1 Tricyclic sulfonamide compounds and methods of making and using same
11/15/2012WO2012154676A1 Partially saturated tricyclic compounds and methods of making and using same
11/15/2012WO2012154627A2 Light delivery device and related compositions, methods and systems
11/15/2012WO2012154613A1 Improved process for the preparation of d-alpha-tocotrienol from natural extracts
11/15/2012WO2012154610A1 Reactive pi3k kinase inhibitors and uses thereof
11/15/2012WO2012154608A1 Reactive mtor and pi3 kinase inhibitors and uses thereof
11/15/2012WO2012154563A1 Sustained release paracetamol formulations
11/15/2012WO2012154554A1 Fatty acid triterpene derivatives and their uses
11/15/2012WO2012154519A1 Aminopyrimidines as syk inhibitors
11/15/2012WO2012154518A1 Bipyridylaminopyridines as syk inhibitors
11/15/2012WO2012154483A1 Dry powder fosfomycin/tobramycin formulation for inhalation
11/15/2012WO2012154392A1 Metformin salts of salicylic acid and its congeners
11/15/2012WO2012154354A1 Cgrp receptor antagonists
11/15/2012WO2012154353A1 Macrocyclic triazine compounds for the treatment of hepatitis c
11/15/2012WO2012154340A1 Use of a2b adenosine receptor antagonists for treating heart failure and arrhythmia in post-myocardial infarction patients
11/15/2012WO2012154321A1 Compounds and pharmaceutical compositions for the treatment of viral infections
11/15/2012WO2012154274A1 Triazolopyridine compounds as pim kinase inhibitors
11/15/2012WO2012154271A2 Method and cells for identifying rig-i pathway regulators
11/15/2012WO2012154261A1 Compounds and methods of treating diabetes
11/15/2012WO2012154249A1 Substituted aminobutyric derivatives as neprilysin inhibitors
11/15/2012WO2012154204A1 Hydroxamic acid derivatives and their use in the treatment of bacterial infections
11/15/2012WO2012154194A1 Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
11/15/2012WO2012154174A1 Methods for treating insomnia
11/15/2012WO2012154126A1 A slow-releasing hydrogen sulphide donor in a method for the treatment of cancer
11/15/2012WO2012154122A2 A topical formulation for treatment of hyperkeratotic skin
11/15/2012WO2012154077A1 Pharmaceutical composition for the treatment of tuberculosis and other infections, and method for producing said composition
11/15/2012WO2012154076A1 Antibacterially active pharmaceutical composition for parenteral use, and method for producing said composition
11/15/2012WO2012154075A1 Antibacterially active pharmaceutical composition for external use, and method for the production of said composition
11/15/2012WO2012154009A2 Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases
11/15/2012WO2012153950A2 Method for preparing t-butyl 2-((4r,6s)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate
11/15/2012WO2012153884A1 Composition having improved stability for ameliorating acne
11/15/2012WO2012153870A1 Therapeutic material for glaucoma
11/15/2012WO2012153854A1 Cytokine-chemokine modulator
11/15/2012WO2012153832A1 Composition for external skin use for inflammatory diseases
11/15/2012WO2012153827A1 Stable drug composition
11/15/2012WO2012153796A1 Pyrimido-diazepinone compound
11/15/2012WO2012153775A1 Thioxothiazolidine derivative having ras function inhibitory effect
11/15/2012WO2012153768A1 Medicinal agent containing pyrmidobenzothiazin-6-imine derivative or salt thereof for prevention and/or treatment of viral infection
11/15/2012WO2012153729A1 Heteroaromatic ring derivative
11/15/2012WO2012153635A1 Therapeutic muscular dystrophy drug having bubble liposome loaded with morpholino as active ingredient
11/15/2012WO2012153493A1 Photodynamic therapy or diagnostic agent, using infrared-spectrum light
11/15/2012WO2012153492A1 Nptx2 as tumor marker and therapeutic target for cancer
11/15/2012WO2012153396A1 Non-aqueous patch
11/15/2012WO2012153347A2 Oral pharmaceutical composition of olanzapine form 1
11/15/2012WO2012153341A1 A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
11/15/2012WO2012153313A1 Pharmaceutical composition of febuxostat
11/15/2012WO2012153302A1 Antipyretics to enhance tolerability of vesicle-based vaccines
11/15/2012WO2012153288A1 Pharmaceutical topical composition for use in the treatment and/or in the prevention of infections of skin lesions
11/15/2012WO2012153273A1 A process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof
11/15/2012WO2012153193A2 Protein-active agent conjugates and method for preparing the same
11/15/2012WO2012153181A1 Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
11/15/2012WO2012153154A1 Oxetane substituted thieno pyrimidinones
11/15/2012WO2012153135A1 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
11/15/2012WO2012153130A1 Salts of 4 -ethyl-1-(2 - phenylethyl) - 8 -phenoxy - 2, 3 - dihydro - 1h - pyrrolo [3, 2 -c] quinoline and their use for treating infections
11/15/2012WO2012153110A1 Use of bethanechol for treatment of xerostomia
11/15/2012WO2012153076A2 Cosmetic skin treatment method comprising two successive steps
11/15/2012WO2012153071A2 Polysaccharides having a variable degree of functionalization
11/15/2012WO2012152983A1 Phenyl- sulfonyl derivatives as mediators of trpa1 receptor activity for the treatment of pain
11/15/2012WO2012152953A1 Methods to reduce adverse events caused by pharmaceutical preparations comprising plasma derived proteins
11/15/2012WO2012152940A2 Small molecule inhibitors of trpa1
11/15/2012WO2012152918A1 Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
11/15/2012WO2012152915A1 Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
11/15/2012WO2012152910A1 Novel pharmaceutical formulation
11/15/2012WO2012152898A1 Treatment of mastitis
11/15/2012WO2012152885A1 Combination of a statin and a taxane for the treatment of gastric cancer
11/15/2012WO2012152872A1 "biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof"
11/15/2012WO2012152854A1 Metabotropic glutamate receptor modulators
11/15/2012WO2012152837A1 Polymorph of linagliptin benzoate
11/15/2012WO2012152779A1 Process of separating chiral isomers of chroman compounds and their derivatives and precursors
11/15/2012WO2012152763A1 Substituted indazole derivatives active as kinase inhibitors
11/15/2012WO2012152718A1 Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
11/15/2012WO2012152663A1 New hexahydropyrroloimidazolone compounds
11/15/2012WO2012152630A1 Substituted imidazopyridines and the use thereof
11/15/2012WO2012152629A1 Substituted imidazopyridines and imidazopyridazines and the use thereof
11/15/2012WO2012152440A1 Composition for modified release comprising ranolazine
11/15/2012WO2012152317A1 Compounds for use in the treatment of feline retroviral infections
11/15/2012WO2012152295A1 Pyrazolyl compounds for use in reversing reactive gliosis
11/15/2012WO2012152209A1 4-carboxy phenyl retinamidethanolate, preparation method and pharmaceutical composition thereof
11/15/2012WO2012152208A1 Thiazole compound and preparation method and use thereof
1 ... 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 ... 7860